Replies to post #114890 on Biotech Values

[jq1234]

That's what is going to be initially and for a few years. It's difficult to predict MS treatment market longer term. No one thought Copaxone is going to get to this point initially. It depends on long term profile. For new MS drug including Gilenya, you just don't know eventual market potential until after a few years on the market.

[zipjet]

I’m assuming it will never be more than a third- or fourth-line treatment for RRMS

I wonder if they have tried it on PPMS. More likely worth the risk there if it works.

ij